275 related articles for article (PubMed ID: 25634991)
1. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
Bax R; Green S
J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
[TBL] [Abstract][Full Text] [Related]
2. The antibiotic pipeline: reviving research and development and speeding drugs to market.
Luepke KH; Mohr JF
Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic research and development: business as usual?
Harbarth S; Theuretzbacher U; Hackett J;
J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
[TBL] [Abstract][Full Text] [Related]
4. Novel approaches are needed to develop tomorrow's antibacterial therapies.
Spellberg B; Bartlett J; Wunderink R; Gilbert DN
Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
[TBL] [Abstract][Full Text] [Related]
5. Antibiotics in late clinical development.
Fernandes P; Martens E
Biochem Pharmacol; 2017 Jun; 133():152-163. PubMed ID: 27687641
[TBL] [Abstract][Full Text] [Related]
6. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
7. Antibacterial drug discovery: is it all downhill from here?
Projan SJ; Shlaes DM
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
[TBL] [Abstract][Full Text] [Related]
8. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
9. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
Kesselheim AS; Outterson K
Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis to guide orphan drug development.
Lesko LJ
Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
[TBL] [Abstract][Full Text] [Related]
11. Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals.
Bettiol E; Wetherington JD; Schmitt N; Harbarth S;
Antimicrob Agents Chemother; 2015 Jul; 59(7):3695-9. PubMed ID: 25918147
[TBL] [Abstract][Full Text] [Related]
12. How can we improve access to new (and old) antibiotics in Australia?
Cheng AC; Nation RL
Med J Aust; 2013 Jul; 199(2):81-2. PubMed ID: 23879485
[No Abstract] [Full Text] [Related]
13. Antibiotics--an investment worth making?
Christoffersen RE
Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
[TBL] [Abstract][Full Text] [Related]
14. What are the economic barriers of antibiotic R&D and how can we overcome them?
Renwick M; Mossialos E
Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
[No Abstract] [Full Text] [Related]
15. A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens.
Alemayehu D; Quinn J; Cook J; Kunkel M; Knirsch CA
Clin Infect Dis; 2012 Aug; 55(4):562-7. PubMed ID: 22610933
[TBL] [Abstract][Full Text] [Related]
16. How can attrition rates be reduced in cancer drug discovery?
Moreno L; Pearson AD
Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
[TBL] [Abstract][Full Text] [Related]
17. New players join the drug development game.
Lott R
Health Aff (Millwood); 2014 Oct; 33(10):1711-3. PubMed ID: 25288413
[TBL] [Abstract][Full Text] [Related]
18. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
Falagas ME; Fragoulis KN; Karydis I
PLoS One; 2006 Dec; 1(1):e11. PubMed ID: 17183637
[TBL] [Abstract][Full Text] [Related]
19. Trends in antimicrobial drug development: implications for the future.
Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
[TBL] [Abstract][Full Text] [Related]
20. Discovery research: the scientific challenge of finding new antibiotics.
Livermore DM;
J Antimicrob Chemother; 2011 Sep; 66(9):1941-4. PubMed ID: 21700626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
